SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 116.39 |
| Enterprise Value ($M) | 134.36 |
| Book Value ($M) | -162.20 |
| Book Value / Share | -1.63 |
| Price / Book | -0.72 |
| NCAV ($M) | -254.17 |
| NCAV / Share | -2.56 |
| Price / NCAV | -0.46 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -35.04 |
| Return on Assets (ROA) | -0.53 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.33 |
| Current Ratio | 1.52 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 331.56 |
| Assets | 423.53 |
| Liabilities | 585.73 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 147.75 |
| Operating Income | -269.21 |
| Net Income | -284.23 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -315.02 |
| Cash from Investing | 153.66 |
| Cash from Financing | 122.75 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Point72 Asset Management, L.P. | 1.70 | -73.83 | |
| 13G | Armistice Capital, Llc | 9.93 | ||
| 13G/A | Vanguard Group Inc | 7.16 | -25.41 | |
| 13G/A | Primecap Management Co/ca/ | 14.72 | 4.15 | |
| 13G/A | BlackRock Inc. | 7.30 | 1.00 | |
| 13G | Millennium Management Llc | 4.70 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q | ||
| Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 122,360 | 834,625 | 14.66 | |
| 203,897 | 228,110 | 89.39 | |
| 185,420 | 222,272 | 83.42 | |
| 184,281 | 328,193 | 56.15 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| EWTX – Edgewise Therapeutics, Inc. | EXEL – Exelixis, Inc. |
| FDMT – 4D Molecular Therapeutics, Inc. | FNCH – Finch Therapeutics Group, Inc. |
| FUSN – Fusion Pharmaceuticals Inc. |
Financial data and stock pages provided by
Fintel.io